-
The JUPITER trial causes a stir; ACP practice guideline for antidepressant use; testosterone for low libido; continued shortage of Hib vaccine; FDA Actions.
-
-
A new regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel [FLOT]) was tested in a phase II trial in 54 patients with gastric or gastro-esophageal cancer. Response rates were comparable, or perhaps even a little better than those published for other combinations; the toxicity profile appears favorable.
-
Among patients who undergo screening and are diagnosed with prostate cancer, there is a dichotomy between those who are diagnosed after their initial screening (prevalent cases) and those who have cancer detected after subsequent screenings (incident cases).
-
Thalidomide-rituximab was administered to 25 symptomatic patients (20 previously untreated) with Waldenstrom macroglobulinemia. The overall response rate was 72%, and the median time-to-progression for responders was 38 months.
-
The role of bisphosphonates in the treatment and prevention of bone metastases remains incompletely characterized. In the current report, Diel et al detail long-term survival data on patients with known microscopic bone disease more than eight years after adjuvant treatment with clodronate.
-
The risk of recurrent venous thromboembolism (VTE) during extended anticoagulant therapy for thrombophilia remains poorly defined. Investigators analyzed 661 patients with idiopathic VTE who had been randomized to extended prophylaxis after three months of initial anticoagulation using either low intensity (INR 1.5-1.9) or standard intensity (INR 2.0-3.0) anticoagulation.
-
-
Eltabbakh retrospectively reviewed women presenting with clinical stage I endometrial cancer (according to the 1988 FIGO staging) at the University of Vermont.
-
